Social anxiety but not callous-unemotional traits predicts shame coping in conduct disorder

IntroductionConduct disorders are characterized by emotional dysregulation. Both callous-unemotional traits and social anxiety are heightened in conduct disorder patients and are associated with different mechanisms of emotion regulation. Previous evidence has proposed that secondary emotions, such as shame, might also be affected in conduct disorder and that callous-unemotional traits and social anxiety might be related to shame as well as to shame coping. Therefore, the current study investigated links between callous-unemotional traits, social anxiety, shame proneness, and shame coping in adolescent inpatients with conduct disorder.MethodsForty adolescent inpatients with conduct disorders (M = 12.4, SD = 1.4) filled in questionnaires on callous-unemotional traits, social anxiety, shame proneness, and shame coping. Correlational and regression analyses, as well as mediation analyses were performed.ResultsCallous-unemotional traits were not associated with any other construct. Social anxiety showed positive correlations with shame proneness and internalizing as well as externalizing shame coping. Social anxiety was also a significant predictor of internalizing shame coping while controlling for shame proneness and callous-unemotional traits. No predictors emerged for externalizing shame coping. Mediation analyses confirmed that neither shame proneness nor social anxiety mediated the relationship between CU traits and shame coping, as CU traits were not significantly associated with either variable.DiscussionThe findings suggest that social anxiety plays a key role in internalizing shame coping in conduct disorder patients. CU traits appear to be unrelated to shame proneness and shame coping, either directly or indirectly, in conduct disorder.

STAT+: Enliven Therapeutics’ leukemia drug shows promise in new study

A targeted drug from Enliven Therapeutics induced molecular responses in nearly half of patients with advanced leukemia, including higher response rates in patients treated at an earlier stage of their disease.

The updated early-stage study results reported Thursday for the Enliven drug, ELVN-001, compare favorably to a current blockbuster medicine sold by Novartis and an upstart experimental drug recently bought by Merck.

At 24 weeks, an 80 mg, once-daily dose of ELVN-001 achieved a major molecular response in 48% of patients with chronic myeloid leukemia, or CML, a slow-growing cancer that starts in myeloid cells.

Continue to STAT+ to read the full story…

STAT+: ‘Synthetic lethality’ could trigger another round of biotech M&A

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

Never before have I covered so much positive news about pancreatic cancer in such a short period of time. What happens next? Could Revolution Medicines buy Tango Therapeutics? Or, perhaps Bristol Myers Squibb goes all out and acquires Revolution Medicines?

To be clear, neither of these deals has been announced, or even rumored. I’m just playing the biotech M&A speculation game. But a strong case for something to happen can be made in the wake of Monday’s exciting report from Tango. In an early-stage clinical trial, patients with advanced pancreatic cancer benefited more from a combination of two targeted drugs — a PRMT5 inhibitor from Tango and Revolution’s pan-RAS inhibitor — than they might from each drug on its own.

Continue to STAT+ to read the full story…

Evaluating Postpartum Hemorrhage Transfusion Risk With a Machine Learning Model for Informed Consent: Retrospective Cohort Study

<strong>Background:</strong> Postpartum hemorrhage requiring a blood transfusion is a concern for patients and clinicians; its risk and the mode of delivery are important points of discussion before labor. Many high-risk factors associated with postpartum hemorrhage are known prior to delivery and are often unpreventable. Delivery plans are influenced by the patient’s medical history, their preferences, and clinical decision-making. Informed consent regarding known risk factors for postpartum hemorrhage will help guide delivery care plans and mitigate risk. Machine learning models have been used to predict postpartum hemorrhage; however, translation into clinical support tools is challenging. Shared decision-making discussions can be facilitated with machine learning model–based clinical support tools predicting postpartum hemorrhage requiring a transfusion. <strong>Objective:</strong> We sought to develop a machine learning model for prediction of postpartum hemorrhage requiring a transfusion. Specifically, we sought to evaluate the model’s accuracy in predicting a patient’s postpartum transfusion risk based on delivery mode, whether labor was induced, and the delivery indications for the purpose of antenatal clinical decision support. Model performance was evaluated on existing structured data and physician-reviewed datasets. <strong>Methods:</strong> A 10-year retrospective cohort of 62,521 births in a community health system was sampled. A convenience sample of 1734 patients was analyzed to predict blood transfusion rate based on delivery mode and delivery indications. XGBoost, random forest, and generalized linear models were trained and compared for performance. Datasets were evaluated using the best-performing XGBoost machine learning model. A prototype clinical support app for physician-patient transfusion risk assessment was developed using the best-performing clinically relevant XGBoost model. <strong>Results:</strong> A generalized linear model, random forest model, and XGBoost model were evaluated. The XGBoost model was trained with an existing dataset extracted from electronic medical records (n=1734). The area under the curve (AUC) was 0.71, precision-recall receiver operating characteristic curve (PR-ROC) was 0.82, and <i>F</i><sub>1</sub> score was 0.80. Performance on a physician-reviewed dataset (n=1734) was as follows: AUC=0.705, PR-ROC=0.78, and <i>F</i><sub>1</sub> score=0.809. Feature importance ranking and prediction were not clinically accurate for the pre-review dataset. <strong>Conclusions:</strong> Machine learning models are useful to determine an individual’s postpartum transfusion risk based on clinically variable and potentially modifiable factors, such as delivery mode, whether labor is induced, and delivery indications. In this study, the XGBoost model had a slightly higher AUC on structured data extracted from electronic medical records than the same dataset after physician review (AUC=0.71 and PR-ROC=0.82 vs AUC=0.705 and PR-ROC=0.78), but a slightly lower <i>F</i><sub>1</sub> score (<i>F</i><sub>1</sub>=0.80 vs <i>F</i><sub>1</sub>=0.809). XGBoost machine learning models trained on clinician-reviewed data can be used to predict postpartum transfusion. Clinically relevant, physician-labeled datasets are important for supervised machine learning model training for use in clinical decision support tools. Further study and external validation are needed prior to clinical use.

Automated Machine Learning Frameworks for Radiomics: Comparative Evaluation Study

<strong>Background:</strong> Automated machine learning (AutoML) frameworks can lower technical barriers for predictive and prognostic model development in radiomics by enabling researchers without programming expertise to build models. However, their effectiveness in addressing radiomics-specific challenges remains unclear. <strong>Objective:</strong> This study aimed to evaluate the performance, efficiency, and accessibility of general-purpose and radiomics-specific AutoML frameworks on diverse radiomics classification tasks, thereby guiding researchers and highlighting development needs for radiomics. <strong>Methods:</strong> A total of 10 public and private radiomics datasets with varied imaging modalities (computed tomography and magnetic resonance imaging), sizes, anatomies, and end points were used. Six general-purpose and 5 radiomics-specific frameworks were tested with predefined parameters using standardized cross-validation. Evaluation metrics included area under the receiver operating characteristic curve, runtime, and qualitative aspects related to software status, accessibility, and interpretability. <strong>Results:</strong> Simplatab, a radiomics-specific tool with a no-code interface, achieved the best overall balance between performance and computational efficiency, recording the highest average test area under the receiver operating characteristic curve (mean 78.46%, SD 12.22%) with a moderate runtime (1.1 h). However, its performance was not statistically superior to the most intensive general-purpose solutions. Most radiomics-specific frameworks were excluded from the performance analysis due to obsolescence, extensive programming requirements, or computational inefficiency. Conversely, general-purpose frameworks demonstrated higher accessibility and ease of implementation. <strong>Conclusions:</strong> While no single framework demonstrated absolute predictive superiority, Simplatab provides an effective balance of performance, efficiency, and accessibility for radiomics classification problems. However, continued efforts are needed to further mature AutoML solutions in the radiomics domain.

Educational Intervention on Environmentally Responsible Inhaler Prescribing Among French General Practitioners: Pilot Pre-Post Study

<strong>Background:</strong> Climate change is expected to cause more than 250,000 deaths annually by 2050 and could increase the prevalence of asthma and chronic obstructive pulmonary disease (COPD) by up to 30%. Pressurized metered-dose inhalers (pMDIs), primarily delivering short-acting beta-2 agonists, generate 15 to 30 times more greenhouse gas emissions than dry powder or soft mist inhalers. In France, short-acting beta-2 agonist pMDIs account for 95% of reliever therapy prescriptions, despite their limited effectiveness in controlling disease symptoms. <strong>Objective:</strong> This study aimed to evaluate the preliminary educational impact of a single educational session on French general practitioners’ awareness and intended prescribing of lower-carbon inhaler alternatives. <strong>Methods:</strong> We conducted a multicenter, single-group pre-post pilot study among 34 general practitioners from 10 multiprofessional health centers in Eastern Occitanie, France, between March and October 2023. Participants were recruited through convenience sampling. The intervention consisted of a one-time 25-minute face-to-face educational session on environmentally responsible inhaler prescribing, aligned with Global Initiative for Asthma (GINA) and Global Initiative for Chronic Obstructive Lung Disease guidelines. Data were collected using self-administered online questionnaires before the intervention and approximately 3 months later. The questionnaires included 2 clinical vignettes, one on asthma and one on COPD, with 3 prescribing questions each. Responses were categorized according to whether they included a pMDI. Changes in responses between baseline and follow-up were analyzed using the Fisher exact test or chi-square test, as appropriate. <strong>Results:</strong> A total of 34 participants completed the baseline questionnaire. Responses including a pMDI decreased from 70.6% (48/68) to 4% (3/68) for reliever therapy (<i>P</i>&lt;.001) and from 21.3% (29/136) to 4.4% (6/136) for maintenance therapy (<i>P</i>=.003). In asthma scenarios, adherence to GINA recommendations improved, with increased responses including inhaled corticosteroid-formoterol for reliever therapy (6%, 2/34 to 38%, 13/34; <i>P</i>=.001) and maintenance therapy (35%, 24/68 to 56%, 38/68; <i>P</i>=.02). No significant improvements were observed for COPD-related prescribing scenarios. The proportion of participants reporting environmental impact as a factor influencing inhaler choice increased from 3% (1/34) to 51% (18/34). Satisfaction was high, with 93% of participants reporting being very satisfied with the intervention. <strong>Conclusions:</strong> This pilot study suggests that a brief educational intervention may improve general practitioners’ knowledge and intended prescribing of lower-carbon inhaler alternatives, particularly in asthma scenarios. However, the outcomes were based on theoretical clinical vignettes rather than real-world prescribing data, and the study was not designed to assess the safety or clinical effectiveness of changing inhaler prescriptions. Future studies should evaluate sustained changes in real-world prescribing while ensuring individualized, clinically appropriate, and safe inhaler choices.